Literature DB >> 9516845

Buthionine sulphoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines.

C P Anderson1, J Tsai, W Chan, C K Park, L Tian, R M Lui, H J Forman, C P Reynolds.   

Abstract

Buthionine sulphoximine (BSO) selectively inhibits glutathione (GSH) synthesis and may enhance the antineuroblastoma activity of melphalan (L-PAM). We determined the cytotoxicity of BSO (dose range 0-1000 microM) alone and in combination with L-PAM (dose range 0-0 microM) in a panel of 18 human neuroblastoma cell lines. BSO alone was highly cytotoxic with 16/18 neuroblastoma cell lines having IC90 values (range 2.1- > 1000 microM) below the clinically achievable steady-state plasma level of 500 microM BSO. Maximal cell killing correlated with GSH levels decreased to less than 10% baseline, and was partially reversed by the addition of exogenous anti-oxidants (GSH, vitamin E and ascorbate). Fluorocytometric analysis of DNA fragments by the Tunnel method detected 92% of a BSO sensitive cell line in apoptosis after a 48 h exposure to 500 microM BSO. The combination of L-PAM and BSO synergistically enhanced the cell killing of L-PAM alone by > 1-3 logs (combination index < 1). We conclude that BSO has significant single-agent cytotoxicity against neuroblastoma and enhances cell killing when combined with L-PAM.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9516845     DOI: 10.1016/s0959-8049(97)00203-7

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  14 in total

1.  Combined Gene Expression and RNAi Screening to Identify Alkylation Damage Survival Pathways from Fly to Human.

Authors:  Alfeu Zanotto-Filho; Ravi Dashnamoorthy; Eva Loranc; Luis H T de Souza; José C F Moreira; Uthra Suresh; Yidong Chen; Alexander J R Bishop
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

2.  Absence of MGST1 mRNA and protein expression in human neuroblastoma cell lines and primary tissue.

Authors:  Michael J Kelner; Mitchell B Diccianni; Alice L Yu; Mary R Rutherford; Leita A Estes; Ralf Morgenstern
Journal:  Free Radic Biol Med       Date:  2014-01-29       Impact factor: 7.376

3.  Increased chemosensitivity and elevated reactive oxygen species are mediated by glutathione reduction in glutamine deprived neuroblastoma cells.

Authors:  Sakurako Izaki; Hiroaki Goto; Shumpei Yokota
Journal:  J Cancer Res Clin Oncol       Date:  2008-01-17       Impact factor: 4.553

4.  Adaptive response to GSH depletion and resistance to L-buthionine-(S,R)-sulfoximine: involvement of Nrf2 activation.

Authors:  Hyang-Rim Lee; Jeong-Min Cho; Dong-ha Shin; Chul Soon Yong; Han-Gon Choi; Nobunao Wakabayashi; Mi-Kyoung Kwak
Journal:  Mol Cell Biochem       Date:  2008-06-28       Impact factor: 3.396

Review 5.  Glutathione: overview of its protective roles, measurement, and biosynthesis.

Authors:  Henry Jay Forman; Hongqiao Zhang; Alessandra Rinna
Journal:  Mol Aspects Med       Date:  2008-08-30

Review 6.  Neuroblastoma: evolving therapies for a disease with many faces.

Authors:  Robert E Goldsby; Katherine K Matthay
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 7.  Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.

Authors:  Gergely Szakács; Matthew D Hall; Michael M Gottesman; Ahcène Boumendjel; Remy Kachadourian; Brian J Day; Hélène Baubichon-Cortay; Attilio Di Pietro
Journal:  Chem Rev       Date:  2014-04-23       Impact factor: 60.622

8.  A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma.

Authors:  Judith G Villablanca; Samuel L Volchenboum; Hwangeui Cho; Min H Kang; Susan L Cohn; Clarke P Anderson; Araz Marachelian; Susan Groshen; Denice Tsao-Wei; Katherine K Matthay; John M Maris; Charlotte E Hasenauer; Scarlett Czarnecki; Hollie Lai; Fariba Goodarzian; Hiro Shimada; Charles Patrick Reynolds
Journal:  Pediatr Blood Cancer       Date:  2016-04-19       Impact factor: 3.167

9.  Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells.

Authors:  Mariia Yuneva; Nicola Zamboni; Peter Oefner; Ravi Sachidanandam; Yuri Lazebnik
Journal:  J Cell Biol       Date:  2007-07-02       Impact factor: 10.539

10.  The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma.

Authors:  A Tagde; H Singh; M H Kang; C P Reynolds
Journal:  Blood Cancer J       Date:  2014-07-18       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.